Quoin Pharmaceuticals Ltd. Accumulated Other Comprehensive Income
Quoin Pharmaceuticals Ltd. (QNRX) had Accumulated Other Comprehensive Income of -$582 as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-14
- 2026-06-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$582.00.
- 2026-03-31: Accumulated Other Comprehensive Income (Loss), Net of Tax -$159.00.
- 2025-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax -$613.00.
- 2025-06-30: Accumulated Other Comprehensive Income (Loss), Net of Tax $62.70M.
| Period end | Accumulated Other Comprehensive Income (Loss), Net of Tax |
|---|---|
| 2026-06-30 | -$582.00 10-Q · filed 2026-08-14 |
| 2026-03-31 | -$159.00 10-Q · filed 2026-05-07 |
| 2025-12-31 | -$613.00 10-Q · filed 2026-08-14 |
| 2025-06-30 | $62.70M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $59.00M 10-Q · filed 2025-05-13 |
| 2024-12-31 | $55.20M 10-K · filed 2025-03-13 |
| 2024-09-30 | -$52.90M 10-Q · filed 2024-11-08 |
| 2024-06-30 | $50.50M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $48.50M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $46.20M 10-K · filed 2024-03-14 |
| 2023-09-30 | $44.20M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $42.20M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $40.10M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $37.50M 10-K · filed 2023-03-15 |
| 2022-09-30 | $35.50M 6-K · filed 2022-11-10 |
| 2022-06-30 | $32.40M 6-K · filed 2022-08-18 |
| 2021-12-31 | $28.10M 20-F · filed 2022-04-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 |